Revenue Showdown: Perrigo Company plc vs Travere Therapeutics, Inc.

Perrigo vs Travere: A Decade of Revenue Trends

__timestampPerrigo Company plcTravere Therapeutics, Inc.
Wednesday, January 1, 2014406080000028203205
Thursday, January 1, 2015460390000099892000
Friday, January 1, 20165280600000133591000
Sunday, January 1, 20174946200000154937000
Monday, January 1, 20184731700000164246000
Tuesday, January 1, 20194837400000175338000
Wednesday, January 1, 20205063300000198321000
Friday, January 1, 20214138700000227490000
Saturday, January 1, 20224451600000212018000
Sunday, January 1, 20234655600000145238000
Loading chart...

Cracking the code

Revenue Dynamics: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, Perrigo Company plc and Travere Therapeutics, Inc. have showcased contrasting revenue trajectories over the past decade. From 2014 to 2023, Perrigo's revenue has consistently dwarfed that of Travere, with Perrigo averaging around 30 times more revenue annually. Perrigo's peak came in 2016, with a revenue surge of approximately 13% from 2014, while Travere's revenue growth was more modest, peaking in 2021 with an increase of over 700% from its 2014 figures.

Despite Perrigo's dominance, Travere's growth rate is noteworthy, reflecting its strategic focus on niche markets. As the industry evolves, these revenue trends highlight the diverse strategies and market positions of these two companies. Investors and industry watchers should keep an eye on how these dynamics play out in the coming years.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025